The White House is expected to announce on Tuesday (30) the launch of TrumpRx, a drug sales portal aimed at the end consumer, according to information published by the Wall Street Journal . The project also includes a partnership with Pfizer, which has committed to reducing the prices of some of its drugs in the United States. President Donald Trump will participate in the official announcement, accompanied by the pharmaceutical company’s CEO.
The website will allow American citizens to purchase medications directly from a government-run portal, paying cash for certain products. Prices would be reduced through negotiations conducted by the federal government itself. It’s still unclear how many and which medications will be included on the platform, nor whether it will actually benefit the majority of the population, already covered by private health insurance, Medicare, or Medicaid.
The initiative represents another step by the White House in its attempt to address the high costs of the American pharmaceutical industry, a recurring topic in public debate and generating strong political pressure. The presence of Pfizer’s CEO at the announcement reinforces the intention to demonstrate industry support for the project.
Despite the expectation surrounding the promised discounts, health experts note that the measure may have limited impact. This is because a significant portion of consumers already have insurance coverage, which could reduce the attractiveness of TrumpRx as a purchasing alternative.
The official announcement will provide more details about how the site works and the terms and conditions agreed with Pfizer, a company that occupies a prominent position in the global pharmaceutical market.
Source: www.brasil247.com